ADCY1 and diabetes mellitus: In vitro experiments revealed distinct responses in diabetic rats compared to normal rats, thereby suggesting that diabetes modulates ghrelin efficacy via the cyclic adenosine monophosphate (cAMP) pathway and adenylate cyclase (AC) activity.